3.320USD-9.04%Mkt Cap: 145.72M USDP/E: 22.132d ago
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.…
Anbio Biotechnology (NASDAQ: NNNN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 27 employees.
The shares were at 3.320 USD on 20 November 2026, down 88.0% over 52 weeks. Its 52-week range is 3.090 USD to 44.73 USD: the price is 92.6% below the high and 7.4% above the low.
At a market capitalisation of 145.72M USD, it trades at 22.1 times trailing earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 48.3, a discount of 54% for NNNN.
Anbio Biotechnology reports return on equity of 21.2%, an operating margin of 66.7% and revenue up 73.9% year over year.
It holds more cash than debt, a net cash position of 11.90M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.